Pfizer strikes $10.5 billion oncology deal with Chinese biotech - Life Sciences Intellectual Property Review
Pfizer strikes $10.5 billion oncology deal with Chinese biotech Life Sciences Intellectual Property Review
Pfizer strikes $10.5 billion oncology deal with Chinese biotech Life Sciences Intellectual Property Review
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.